Elicio Therapeutics股价因1000万美元证券发行而下跌

Elicio Therapeutics (NASDAQ:ELTX) shares fell over 18% premarket as the biotechnology company announced an offering to raise around $10.0 million.

The company entered into definitive securities purchase agreements with institutional investors for the purchase of 1,261,830 shares of its common stock and accompanying warrants to purchase up to 1,261,830 shares, at a purchase price of $7.925 per share and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules.

The warrants will have an exercise price of $7.80 per share, will be exercisable immediately upon issuance, and will expire five years from the initial exercise date.

Elicio currently intends to use the net proceeds from the offering for working capital and other general corporate purposes.

The offering is expected to occur on or about January 30, 2025, subject to the satisfaction of customary closing conditions.

More on Elicio Therapeutics

• Seeking Alpha’s Quant Rating on Elicio Therapeutics
• Historical earnings data for Elicio Therapeutics
• Financial information for Elicio Therapeutics